Chronic ulcerative colitis and colorectal cancer

Cancer Letters

Volumn 345, Issue 2, 2014, Pages 235-241

  Rogler, Gerhard ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Cancer risk; Colorectal cancer; Crohn's disease; Dysplasia; Inflammation associated cancer; Ulcerative colitis

Indexed keywords

ANTIINFLAMMATORY AGENT; BETA CATENIN; GLYCOGEN SYNTHASE KINASE 3BETA; IMMUNOSUPPRESSIVE AGENT; K RAS PROTEIN; MESALAZINE; PROTEIN P53; REACTIVE OXYGEN METABOLITE; STEROID; WNT PROTEIN;

CANCER PATIENT; CANCER RISK; CARCINOGENESIS; CHRONIC INFLAMMATION; COLON POLYPOSIS; COLORECTAL ADENOMA; COLORECTAL CANCER; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DYSPLASIA; GENE MUTATION; HIGH RISK PATIENT; HUMAN; ILEOANAL ANASTOMOSIS; INCIDENCE; INFLAMMATORY INFILTRATE; INTESTINE EPITHELIUM CELL; INTESTINE FLORA; LOW RISK POPULATION; NONHUMAN; ONCOGENE K RAS; PATHOPHYSIOLOGY; POPULATION RESEARCH; PRIORITY JOURNAL; PROCTOCOLECTOMY; PROGNOSIS; SHORT SURVEY; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; ULCERATIVE COLITIS;

CANCER RISK; COLORECTAL CANCER; CROHN'S DISEASE; DYSPLASIA; INFLAMMATION-ASSOCIATED CANCER; ULCERATIVE COLITIS;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION MEDIATORS; PROCTOCOLECTOMY, RESTORATIVE; REACTIVE OXYGEN SPECIES; RISK FACTORS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84896713816     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.07.032     Document Type: Review

References (113)

1. Muller K.E., Lakatos P.L., Arato A., Kovacs J.B., Varkonyi A., Szucs D., Szakos E., Solyom E., Kovacs M., Polgar M., Nemes E., Guthy I., Tokodi I., Toth G., Horvath A., Tarnok A., Csoszanszki N., Balogh M., Vass N., Bodi P., Dezsofi A., Gardos L., Micskey E., Papp M., Cseh A., Szabo D., Voros P., Veres G. Incidence, Paris classification and follow-up in a nationwide, incident cohort of pediatric patients with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 2013.
2. Zhao J., Ng S.C., Lei Y., Yi F., Li J., Yu L., Zou K., Dan Z., Dai M., Ding Y., Song M., Mei Q., Fang X., Liu H., Shi Z., Zhou R., Xia M., Wu Q., Xiong Z., Zhu W., Deng L., Kamm M.A., Xia B. First prospective, population-based inflammatory bowel disease incidence study in Mainland of China: the emergence of "western" disease. Inflamm. Bowel Dis. 2013.
3. Burisch J., Pedersen N., Cukovic-Cavka S., Brinar M., Kaimakliotis I., Duricova D., Shonova O., Vind I., Avnstrom S., Thorsgaard N., Andersen V., Krabbe S., Dahlerup J.F., Salupere R., Nielsen K.R., Olsen J., Manninen P., Collin P., Tsianos E.V., Katsanos K.H., Ladefoged K., Lakatos L., Bjornsson E., Ragnarsson G., Bailey Y., Odes S., Schwartz D., Martinato M., Lupinacci G., Milla M., De Padova A., D'Inca R., Beltrami M., Kupcinskas L., Kiudelis G., Turcan S., Tighineanu O., Mihu I., Magro F., Barros L.F., Goldis A., Lazar D., Belousova E., Nikulina I., Hernandez V., Martinez-Ares D., Almer S., Zhulina Y., Halfvarson J., Arebi N., Sebastian S., Lakatos P.L., Langholz E., Munkholm P. East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. Gut 2013.
4. Ng S.C., Tang W., Ching J.Y., Wong M., Chow C.M., Hui A.J., Wong T.C., Leung V.K., Tsang S.W., Yu H.H., Li M.F., Ng K.K., Kamm M.A., Studd C., Bell S., Leong R., de Silva H.J., Kasturiratne A., Mufeena M.N., Ling K.L., Ooi C.J., Tan P.S., Ong D., Goh K.L., Hilmi I., Pisespongsa P., Manatsathit S., Rerknimitr R., Aniwan S., Wang Y.F., Ouyang Q., Zeng Z., Zhu Z., Chen M.H., Hu P.J., Wu K., Wang X., Simadibrata M., Abdullah M., Wu J.C., Sung J.J., Chan F.K. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-Pacific Crohn's and colitis epidemiology study. Gastroenterology 2013, 145:158-165. e152.
5. Adamiak T., Walkiewicz-Jedrzejczak D., Fish D., Brown C., Tung J., Khan K., Faubion W., Park R., Heikenen J., Yaffee M., Rivera-Bennett M.T., Wiedkamp M., Stephens M., Noel R., Nugent M., Nebel J., Simpson P., Kappelman M.D., Kugathasan S. Incidence, clinical characteristics, and natural history of pediatric IBD in Wisconsin: a population-based epidemiological study. Inflamm. Bowel Dis. 2013, 19:1218-1223.
6. Malmborg P., Grahnquist L., Lindholm J., Montgomery S., Hildebrand H. Increasing incidence of paediatric inflammatory bowel disease in northern Stockholm County, 2002-2007. J. Pediatr. Gastroenterol. Nutr. 2013, 57:29-34.
7. Zeng Z., Zhu Z., Yang Y., Ruan W., Peng X., Su Y., Peng L., Chen J., Yin Q., Zhao C., Zhou H., Yuan S., Hao Y., Qian J., Ng S.C., Chen M., Hu P. Incidence and clinical characteristics of inflammatory bowel disease in a developed region of Guangdong Province, China: a prospective population-based study. J. Gastroenterol. Hepatol. 2013, 28:1148-1153.
8. Martin-de-Carpi J., Rodriguez A., Ramos E., Jimenez S., Martinez-Gomez M.J., Medina E. Increasing incidence of pediatric inflammatory bowel disease in Spain (1996-2009): the SPIRIT registry. Inflamm. Bowel Dis. 2013, 19:73-80.
9. Hartnett L., Egan L.J. Inflammation, DNA methylation and colitis-associated cancer. Carcinogenesis 2012, 33:723-731.
10. Grivennikov S.I. Inflammation and colorectal cancer: colitis-associated neoplasia. Semin. Immunopathol. 2013, 35:229-244.
11. Gyde S.N., Prior P., Allan R.N., Stevens A., Jewell D.P., Truelove S.C., Lofberg R., Brostrom O., Hellers G. Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centres. Gut 1988, 29:206-217.
12. Brostrom O., Lofberg R., Nordenvall B., Ost A., Hellers G. The risk of colorectal cancer in ulcerative colitis. An epidemiologic study. Scand. J. Gastroenterol. 1987, 22:1193-1199.
13. Porschen R., Strohmeyer G. Risk of colorectal cancer in ulcerative colitis - monitoring strategies and identification of risk patients. Z. Gastroenterol. 1992, 30:585-593.
14. Collins R.H., Feldman M., Fordtran J.S. Colon cancer, dysplasia, and surveillance in patients with ulcerative colitis. A critical review. N. Engl. J. Med. 1987, 316:1654-1658.
15. Lofberg R., Brostrom O., Karlen P., Tribukait B., Ost A. Colonoscopic surveillance in long-standing total ulcerative colitis - a 15-year follow-up study. Gastroenterology 1990, 99:1021-1031.
16. Eaden J.A., Abrams K.R., Mayberry J.F. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001, 48:526-535.
17. Winther K.V., Jess T., Langholz E., Munkholm P., Binder V. Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin. Gastroenterol. Hepatol. 2004, 2:1088-1095.
18. Rutter M.D., Saunders B.P., Wilkinson K.H., Rumbles S., Schofield G., Kamm M.A., Williams C.B., Price A.B., Talbot I.C., Forbes A. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 2006, 130:1030-1038.
19. Soderlund S., Brandt L., Lapidus A., Karlen P., Brostrom O., Lofberg R., Ekbom A., Askling J. Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterology 2009, 136:1561-1567. quiz 1818-1569.
20. Manninen P., Karvonen A.L., Huhtala H., Aitola P., Hyoty M., Nieminen I., Hemminki H., Collin P. The risk of colorectal cancer in patients with inflammatory bowel diseases in Finland: a follow-up of 20years. J. Crohns Colitis 2013.
21. Beaugerie L., Svrcek M., Seksik P., Bouvier A.M., Simon T., Allez M., Brixi H., Gornet J.M., Altwegg R., Beau P., Duclos B., Bourreille A., Faivre J., Peyrin-Biroulet L., Flejou J.F., Carrat F. Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology 2013, 145:166-175. e168.
22. Selinger C.P., Andrews J.M., Titman A., Norton I., Jones D.B., McDonald C., Barr G., Selby W., Leong R.W. Long-term follow up reveals low incidence of colorectal cancer, but frequent need for resection, among Australian patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 2013.
23. Jess T., Rungoe C., Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin. Gastroenterol. Hepatol. 2012.
24. Brentnall T.A., Haggitt R.C., Rabinovitch P.S., Kimmey M.B., Bronner M.P., Levine D.S., Kowdley K.V., Stevens A.C., Crispin D.A., Emond M., Rubin C.E. Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1996, 110:331-338.
25. Terg R., Sambuelli A., Coronel E., Mazzuco J., Cartier M., Negreira S., Munoz A., Gil A., Miguez C., Huernos S., Romero G., Goncalvez S., Levi D., Abecasis R. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis and the risk of developing malignancies. A large prospective study. Acta Gastroenterol. Latinoam. 2008, 38:26-33.
26. Pekow J.R., Hetzel J.T., Rothe J.A., Hanauer S.B., Turner J.R., Hart J., Noffsinger A., Huo D., Rubin D.T. Outcome after surveillance of low-grade and indefinite dysplasia in patients with ulcerative colitis. Inflamm. Bowel Dis. 2010, 16:1352-1356.
27. Navaneethan U., Venkatesh P.G., Lashner B.A., Remzi F.H., Shen B., Kiran R.P. Temporal trends in colon neoplasms in patients with primary sclerosing cholangitis and ulcerative colitis. J. Crohns Colitis 2012.
28. Hirschfield G.M., Karlsen T.H., Lindor K.D., Adams D.H. Primary sclerosing cholangitis. Lancet 2013.
29. Karlsen T.H., Boberg K.M. Update on primary sclerosing cholangitis. J. Hepatol. 2013.
30. Singh S., Talwalkar J.A. Primary sclerosing cholangitis: diagnosis, prognosis, and management. Clin. Gastroenterol. Hepatol. 2013.
31. Chaparro M., Trapero-Marugan M., Guijarro M., Lopez C., Moreno-Otero R., Gisbert J.P. Dysplasia and colorectal cancer in a patient with ulcerative colitis and primary sclerosing cholangitis: a case report and a short review of the literature. J. Crohns Colitis 2013, 7:e61-65.
32. Rutter M.D., Riddell R.H. Colorectal dysplasia in inflammatory bowel disease: a clinicopathological perspective. Clin. Gastroenterol. Hepatol. 2013.
33. Kiran R.P., Ahmed Ali U., Nisar P.J., Khoury W., Gu J., Shen B., Remzi F.H., Hammel J.P., Lavery I.C., Fazio V.W., Goldblum J.R. Risk and location of cancer in patients with preoperative colitis-associated dysplasia undergoing proctocolectomy. Ann. Surg. 2013.
34. Chen Y.X., Qiao L. Adenoma-like and non-adenoma-like dysplasia-associated lesion or mass in ulcerative colitis. J. Dig. Dis. 2013, 14:157-159.
35. Cairns S.R., Scholefield J.H., Steele R.J., Dunlop M.G., Thomas H.J., Evans G.D., Eaden J.A., Rutter M.D., Atkin W.P., Saunders B.P., Lucassen A., Jenkins P., Fairclough P.D., Woodhouse C.R. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from. Gut 2002, 59(2010):666-689.
36. Zisman T.L., Bronner M.P., Rulyak S., Kowdley K.V., Saunders M., Lee S.D., Ko C., Kimmey M.B., Stevens A., Maurer J., Brentnall T.A. Prospective study of the progression of low-grade dysplasia in ulcerative colitis using current cancer surveillance guidelines. Inflamm. Bowel Dis. 2012, 18:2240-2246.
37. Basseri R.J., Basseri B., Vassilaki M.E., Melmed G.Y., Ippoliti A., Vasiliauskas E.A., Fleshner P.R., Lechago J., Hu B., Berel D., Targan S.R., Papadakis K.A. Colorectal cancer screening and surveillance in Crohn's colitis. J. Crohns Colitis 2012, 6:824-829.
38. Lashner B.A., Provencher K.S., Bozdech J.M., Brzezinski A. Worsening risk for the development of dysplasia or cancer in patients with chronic ulcerative colitis. Am. J. Gastroenterol. 1995, 90:377-380.
39. Loftus E.V. Epidemiology and risk factors for colorectal dysplasia and cancer in ulcerative colitis. Gastroenterol. Clin. North Am. 2006, 35:517-531.
40. Biancone L., Michetti P., Travis S., Escher J.C., Moser G., Forbes A., Hoffmann J.C., Dignass A., Gionchetti P., Jantschek G., Kiesslich R., Kolacek S., Mitchell R., Panes J., Soderholm J., Vucelic B., Stange E. European evidence-based consensus on the management of ulcerative colitis: special situations. J. Crohns Colitis 2008, 2:63-92.
41. Ikehata A. A case of colitis-associated colorectal carcinoma developing only two years after the first symptoms of ulcerative colitis. J. Gastroenterol. 2007, 42:854-855.
42. Gupta R.B., Harpaz N., Itzkowitz S., Hossain S., Matula S., Kornbluth A., Bodian C., Ullman T. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2007, 133:1099-1105. quiz 1340-1091.
43. Goldstone R., Itzkowitz S., Harpaz N., Ullman T. Dysplasia is more common in the distal than proximal colon in ulcerative colitis surveillance. Inflamm. Bowel Dis. 2011.
44. Goldstone R., Itzkowitz S., Harpaz N., Ullman T. Progression of low-grade dysplasia in ulcerative colitis: effect of colonic location. Gastrointest. Endosc. 2011, 74:1087-1093.
45. Kavanagh D.O., Carter M.C., Keegan D., Doherty G., Smith M.J., Hyland J.M., Mulcahy H., Sheahan K., O'Connell P.R., O'Donoghue D.P., Winter D.C. Management of colorectal cancer in patients with inflammatory bowel disease. Tech. Coloproctol. 2013.
46. Matula S., Croog V., Itzkowitz S., Harpaz N., Bodian C., Hossain S., Ullman T. Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine. Clin. Gastroenterol. Hepatol. 2005, 3:1015-1021.
47. Eaden J. Review article: the data supporting a role for aminosalicylates in the chemoprevention of colorectal cancer in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 2003, 18(Suppl 2):15-21.
48. Mehta S.J., Silver A.R., Lindsay J.O. Review article: strategies for the management of chronic unremitting ulcerative colitis. Aliment. Pharmacol. Ther. 2013, 38:77-97.
49. Seidelin J.B., Coskun M., Nielsen O.H. Mucosal healing in ulcerative colitis: pathophysiology and pharmacology. Adv. Clin. Chem. 2013, 59:101-123.
50. Nieminen U., Jussila A., Nordling S., Mustonen H., Farkkila M.A. Inflammation and disease duration have a cumulative effect on the risk of dysplasia and carcinoma in IBD: a case-control observational study based on registry data. Int. J. Cancer 2013.
51. Arthur J.C., Jobin C. The complex interplay between inflammation, the microbiota and colorectal cancer. Gut Microbes 2013, 4:253-258.
52. Lichtenstein G.R., Rutgeerts P. Importance of mucosal healing in ulcerative colitis. Inflamm. Bowel Dis. 2010, 16:338-346.
53. Actis G.C., Pellicano R., David E., Sapino A. Azathioprine, mucosal healing in ulcerative colitis, and the chemoprevention of colitic cancer: a clinical-practice-based forecast. Inflamm. Allergy Drug Targets 2010, 9:6-9.
54. Velayos F.S., Loftus E.V., Jess T., Harmsen W.S., Bida J., Zinsmeister A.R., Tremaine W.J., Sandborn W.J. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology 2006, 130:1941-1949.
55. Rubin D.T., LoSavio A., Yadron N., Huo D., Hanauer S.B. Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin. Gastroenterol. Hepatol. 2006, 4:1346-1350.
56. Bernstein C.N., Nugent Z., Blanchard J.F. 5-Aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study. Am. J. Gastroenterol. 2011, 106:731-736.
57. Lyakhovich A., Gasche C. Systematic review: molecular chemoprevention of colorectal malignancy by mesalazine. Aliment. Pharmacol. Ther. 2010, 31:202-209.
58. Cottliar A., Fundia A., Boerr L., Sambuelli A., Negreira S., Gil A., Gomez J.C., Chopita N., Bernedo A., Slavutsky I. High frequencies of telomeric associations, chromosome aberrations, and sister chromatid exchanges in ulcerative colitis. Am. J. Gastroenterol. 2000, 95:2301-2307.
59. Fujiwara I., Yashiro M., Kubo N., Maeda K., Hirakawa K. Ulcerative colitis-associated colorectal cancer is frequently associated with the microsatellite instability pathway. Dis. Colon Rectum 2008, 51:1387-1394.
60. Lovig T., Andersen S.N., Clausen O.P., Rognum T.O. Microsatellite instability in long-standing ulcerative colitis. Scand. J. Gastroenterol. 2007, 42:586-591.
61. Koizumi K., Alonso S., Miyaki Y., Okada S., Ogura H., Shiiya N., Konishi F., Taya T., Perucho M., Suzuki K. Array-based identification of common DNA methylation alterations in ulcerative colitis. Int. J. Oncol. 2012, 40:983-994.
62. Thorsteinsdottir S., Gudjonsson T., Nielsen O.H., Vainer B., Seidelin J.B. Pathogenesis and biomarkers of carcinogenesis in ulcerative colitis. Nat. Rev. Gastroenterol. Hepatol. 2011, 8:395-404.
63. Allen P.B., Kamm M.A., De Cruz P., Desmond P.V. Dysplastic lesions in ulcerative colitis: changing paradigms. Inflamm. Bowel Dis. 2010, 16:1978-1983.
64. Sato Y., Takagi S., Aizawa H., Yokoyama H., Takahashi S., Kakuta Y., Tosa M., Mochida A., Nomura E., Kinouchi Y., Shimosegawa T. Useful endoscopic findings for early diagnosis of ulcerative colitis associated colorectal cancer. Endoscopy 2008, 40(Suppl 2):E71-72.
65. Pack S.C., Kim H.R., Lim S.W., Kim H.Y., Ko J.Y., Lee K.S., Hwang D., Park S.I., Kang H., Park S.W., Hong G.Y., Hwang S.M., Shin M.G., Lee S. Usefulness of plasma epigenetic changes of five major genes involved in the pathogenesis of colorectal cancer. Int. J. Colorectal Dis. 2013, 28:139-147.
66. Ullman T.A., Itzkowitz S.H. Intestinal inflammation and cancer. Gastroenterology 2011, 140:1807-1816.
67. Marnett L.J. Oxyradicals and DNA damage. Carcinogenesis 2000, 21:361-370.
68. McKenzie S.J., Baker M.S., Buffinton G.D., Doe W.F. Evidence of oxidant-induced injury to epithelial cells during inflammatory bowel disease. J. Clin. Invest. 1996, 98:136-141.
69. D'Inca R., Cardin R., Benazzato L., Angriman I., Martines D., Sturniolo G.C. Oxidative DNA damage in the mucosa of ulcerative colitis increases with disease duration and dysplasia. Inflamm. Bowel Dis. 2004, 10:23-27.
70. Hofseth L.J., Khan M.A., Ambrose M., Nikolayeva O., Xu-Welliver M., Kartalou M., Hussain S.P., Roth R.B., Zhou X., Mechanic L.E., Zurer I., Rotter V., Samson L.D., Harris C.C. The adaptive imbalance in base excision-repair enzymes generates microsatellite instability in chronic inflammation. J. Clin. Invest. 2003, 112:1887-1894.
71. Hussain S.P., Hofseth L.J., Harris C.C. Radical causes of cancer. Nat. Rev. Cancer 2003, 3:276-285.
72. Chiba T., Marusawa H., Ushijima T. Inflammation-associated cancer development in digestive organs: mechanisms and roles for genetic and epigenetic modulation. Gastroenterology 2012, 143:550-563.
73. Ustyugova I.V., Zhi L., Abramowitz J., Birnbaumer L., Wu M.X. IEX-1 deficiency protects against colonic cancer. Mol. Cancer Res. 2012, 10:760-767.
74. Hofmann C., Obermeier F., Artinger M., Hausmann M., Falk W., Schoelmerich J., Rogler G., Grossmann J. Cell-cell contacts prevent anoikis in primary human colonic epithelial cells. Gastroenterology 2007, 132:587-600.
75. Grossmann J. Molecular mechanisms of "detachment-induced apoptosis-Anoikis". Apoptosis 2002, 7:247-260.
76. Kiran R.P., Nisar P.J., Goldblum J.R., Fazio V.W., Remzi F.H., Shen B., Lavery I.C. Dysplasia associated with Crohn's colitis: segmental colectomy or more extended resection?. Ann. Surg. 2012, 256:221-226.
77. Galandiuk S., Rodriguez-Justo M., Jeffery R., Nicholson A.M., Cheng Y., Oukrif D., Elia G., Leedham S.J., McDonald S.A., Wright N.A., Graham T.A. Field cancerization in the intestinal epithelium of patients with Crohn's ileocolitis. Gastroenterology 2012, 142:855-864. e858.
78. Willenbucher R.F., Aust D.E., Chang C.G., Zelman S.J., Ferrell L.D., Moore D.H., Waldman F.M. Genomic instability is an early event during the progression pathway of ulcerative-colitis-related neoplasia. Am. J. Pathol. 1999, 154:1825-1830.
79. Redston M.S., Papadopoulos N., Caldas C., Kinzler K.W., Kern S.E. Common occurrence of APC and K-ras gene mutations in the spectrum of colitis-associated neoplasias. Gastroenterology 1995, 108:383-392.
80. Tarmin L., Yin J., Harpaz N., Kozam M., Noordzij J., Antonio L.B., Jiang H.Y., Chan O., Cymes K., Meltzer S.J. Adenomatous polyposis coli gene mutations in ulcerative colitis-associated dysplasias and cancers versus sporadic colon neoplasms. Cancer Res. 1995, 55:2035-2038.
81. Yoshimi K., Tanaka T., Serikawa T., Kuramoto T. Tumor suppressor APC protein is essential in mucosal repair from colonic inflammation through angiogenesis. Am. J. Pathol. 2013, 182:1263-1274.
82. Rosman-Urbach M., Niv Y., Birk Y., Smirnoff P., Zusman I., Morgenstern S., Schwartz B. A high degree of aneuploidy, loss of p53 gene, and low soluble p53 protein serum levels are detected in ulcerative colitis patients. Dis. Colon Rectum 2004, 47:304-313.
83. Lashner B.A., Bauer W.M., Rybicki L.A., Goldblum J.R. Abnormal p53 immunohistochemistry is associated with an increased colorectal cancer-related mortality in patients with ulcerative colitis. Am. J. Gastroenterol. 2003, 98:1423-1427.
84. Hussain S.P., Amstad P., Raja K., Ambs S., Nagashima M., Bennett W.P., Shields P.G., Ham A.J., Swenberg J.A., Marrogi A.J., Harris C.C. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res. 2000, 60:3333-3337.
85. Cooks T., Pateras I.S., Tarcic O., Solomon H., Schetter A.J., Wilder S., Lozano G., Pikarsky E., Forshew T., Rozenfeld N., Harpaz N., Itzkowitz S., Harris C.C., Rotter V., Gorgoulis V.G., Oren M. Mutant p53 prolongs NF-kappaB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell 2013, 23:634-646.
86. Wohl P., Hucl T., Drastich P., Kamenar D., Spicak J., Honsova E., Sticova E., Lodererova A., Matous J., Hill M., Kucera M. Epithelial markers of colorectal carcinogenesis in ulcerative colitis and primary sclerosing cholangitis. World J. Gastroenterol. 2013, 19:2234-2241.
87. Brentnall T.A., Crispin D.A., Rabinovitch P.S., Haggitt R.C., Rubin C.E., Stevens A.C., Burmer G.C. Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology 1994, 107:369-378.
88. Burmer G.C., Rabinovitch P.S., Haggitt R.C., Crispin D.A., Brentnall T.A., Kolli V.R., Stevens A.C., Rubin C.E. Neoplastic progression in ulcerative colitis: histology, DNA content, and loss of a p53 allele. Gastroenterology 1992, 103:1602-1610.
89. Yin J., Harpaz N., Tong Y., Huang Y., Laurin J., Greenwald B.D., Hontanosas M., Newkirk C., Meltzer S.J. P53 point mutations in dysplastic and cancerous ulcerative colitis lesions. Gastroenterology 1993, 104:1633-1639.
90. Kim T.O., Park J., Kang M.J., Lee S.H., Jee S.R., Ryu D.Y., Yang K., Yi J.M. DNA hypermethylation of a selective gene panel as a risk marker for colon cancer in patients with ulcerative colitis. Int. J. Mol. Med. 2013, 31:1255-1261.
91. Katsurano M., Niwa T., Yasui Y., Shigematsu Y., Yamashita S., Takeshima H., Lee M.S., Kim Y.J., Tanaka T., Ushijima T. Early-stage formation of an epigenetic field defect in a mouse colitis model, and non-essential roles of T- and B-cells in DNA methylation induction. Oncogene 2012, 31:342-351.
92. Fleisher A.S., Esteller M., Harpaz N., Leytin A., Rashid A., Xu Y., Liang J., Stine O.C., Yin J., Zou T.T., Abraham J.M., Kong D., Wilson K.T., James S.P., Herman J.G., Meltzer S.J. Microsatellite instability in inflammatory bowel disease-associated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch repair gene, hMLH1. Cancer Res. 2000, 60:4864-4868.
93. Hsieh C.J., Klump B., Holzmann K., Borchard F., Gregor M., Porschen R. Hypermethylation of the p16INK4a promoter in colectomy specimens of patients with long-standing and extensive ulcerative colitis. Cancer Res. 1998, 58:3942-3945.
94. Moriyama T., Matsumoto T., Nakamura S., Jo Y., Mibu R., Yao T., Iida M. Hypermethylation of p14 (ARF) may be predictive of colitic cancer in patients with ulcerative colitis. Dis. Colon Rectum 2007, 50:1384-1392.
95. Sartor R.B. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat. Clin. Pract. Gastroenterol. Hepatol. 2006, 3:390-407.
96. Sartor R.B. Microbial and dietary factors in the pathogenesis of chronic, immune-mediated intestinal inflammation. Adv. Exp. Med. Biol. 2006, 579:35-54.
97. Jobin C. Colorectal cancer: CRC - all about microbial products and barrier function?. Nat. Rev. Gastroenterol. Hepatol. 2012, 9:694-696.
98. Arthur J.C., Perez-Chanona E., Muhlbauer M., Tomkovich S., Uronis J.M., Fan T.J., Campbell B.J., Abujamel T., Dogan B., Rogers A.B., Rhodes J.M., Stintzi A., Simpson K.W., Hansen J.J., Keku T.O., Fodor A.A., Jobin C. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 2012, 338:120-123.
99. Grivennikov S.I., Wang K., Mucida D., Stewart C.A., Schnabl B., Jauch D., Taniguchi K., Yu G.Y., Osterreicher C.H., Hung K.E., Datz C., Feng Y., Fearon E.R., Oukka M., Tessarollo L., Coppola V., Yarovinsky F., Cheroutre H., Eckmann L., Trinchieri G., Karin M. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 2012, 491:254-258.
100. Delaunoit T., Limburg P.J., Goldberg R.M., Lymp J.F., Loftus E.V. Colorectal cancer prognosis among patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 2006, 4:335-342.
101. Watanabe T., Konishi T., Kishimoto J., Kotake K., Muto T., Sugihara K. Ulcerative colitis-associated colorectal cancer shows a poorer survival than sporadic colorectal cancer: a nationwide Japanese study. Inflamm. Bowel Dis. 2011, 17:802-808.
102. Inoue T., Murano M., Kuramoto T., Ishida K., Kawakami K., Abe Y., Morita E., Murano N., Toshina K., Nishikawa T., Maemura K., Shimamoto C., Hirata I., Katsu K., Higuchi K. Increased proliferation of middle to distal colonic cells during colorectal carcinogenesis in experimental murine ulcerative colitis. Oncol. Rep. 2007, 18:1457-1462.
103. Sugita A., Greenstein A.J., Ribeiro M.B., Sachar D.B., Bodian C., Panday A.K., Szporn A., Pozner J., Heimann T., Palmer M., et al. Survival with colorectal cancer in ulcerative colitis. A study of 102 cases. Ann. Surg. 1993, 218:189-195.
104. Lavery I.C., Chiulli R.A., Jagelman D.G., Fazio V.W., Weakley F.L. Survival with carcinoma arising in mucosal ulcerative colitis. Ann. Surg. 1982, 195:508-512.
105. Averboukh F., Ziv Y., Kariv Y., Zmora O., Dotan I., Klausner J.M., Rabau M., Tulchinsky H. Colorectal carcinoma in inflammatory bowel disease: a comparison between Crohn's and ulcerative colitis. Colorectal Dis. 2011, 13:1230-1235.
106. Jensen A.B., Larsen M., Gislum M., Skriver M.V., Jepsen P., Norgaard B., Sorensen H.T. Survival after colorectal cancer in patients with ulcerative colitis: a nationwide population-based Danish study. Am. J. Gastroenterol. 2006, 101:1283-1287.
107. Hata K., Watanabe T., Kazama S., Suzuki K., Shinozaki M., Yokoyama T., Matsuda K., Muto T., Nagawa H. Earlier surveillance colonoscopy programme improves survival in patients with ulcerative colitis associated colorectal cancer: results of a 23-year surveillance programme in the Japanese population. Br. J. Cancer 2003, 89:1232-1236.
108. Watanabe T., Ajioka Y., Matsumoto T., Tomotsugu N., Takebayashi T., Inoue E., Iizuka B., Igarashi M., Iwao Y., Ohtsuka K., Kudo S.E., Kobayashi K., Sada M., Hirata I., Murakami K., Nagahori M., Watanabe K., Hida N., Ueno F., Tanaka S., Watanabe M., Hibi T. Target biopsy or step biopsy? Optimal surveillance for ulcerative colitis: a Japanese nationwide randomized controlled trial. J. Gastroenterol. 2011, 46(Suppl. 1):11-16.
109. Watanabe T. Efficacy of probe-based confocal laser endomicroscopy for surveillance in ulcerative colitis endomicroscopy for ulcerative colitis surveillance. Endoscopy 2011, 43:374.
110. Efthymiou M., Taylor A.C., Kamm M.A. Cancer surveillance strategies in ulcerative colitis: the need for modernization. Inflamm. Bowel Dis. 2011, 17:1800-1813.
111. Rubenstein J.H., Waljee A.K., Jeter J.M., Velayos F.S., Ladabaum U., Higgins P.D. Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates. Am. J. Gastroenterol. 2009, 104:2222-2232.
112. Korelitz B.I. Crohn's colitis versus ulcerative colitis: should surveillance for dysplasia and cancer differ?. Nat. Clin. Pract. Gastroenterol. Hepatol. 2009, 6:144-145.
113. Kekilli M., Dagli U., Kalkan I.H., Tunc B., Disibeyaz S., Ulker A., Sahin B. Low incidence of colorectal dysplasia and cancer among patients with ulcerative colitis: a Turkish referral centre study. Scand. J. Gastroenterol. 2010, 45:434-439.